Celularity Inc., a clinical-stage biotechnology company, develops off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer, immune, and infectious diseases. It operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. The company's lead therapeutic programs include CYCART-19, a placental-derived CAR-T therapy, which is in Phase I clinical trial for the treatment of B-cell malignancies; CYNK-001, placental-derived unmodified natural killer (NK) cell that is in Phase I clinical trial to treat acute myeloid leukemia, as well as in Phase I/IIa clinical trial for the treatment of glioblastoma multiforme and COVID-19; CYNK-101, an allogeneic genetically modified NK cell, which is in Phase I clinical trial to treat HER2+ gastric and gastroesophageal cancers; APPL-001, a placenta-derived mesenchymal-like adherent stromal cell that is in a pre-clinical stage for the treatment of Crohn's disease; and PDA-002, a placenta-derived mesenchymal-like adherent stromal cell, which is in pre-clinical stage for the treatment of facioscapulohumeral muscular dystrophy. It also sells and licenses products that are used in surgical and wound care markets, such as Biovance and Interfyl; collects stem cells from umbilical cords and placentas; and provides cells storage under the LifebankUSA brand. The company was incorporated in 2016 and is headquartered in Florham Park, New Jersey.

Celularity Inc.

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity’s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature’s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases. To learn more visit celularity.com.

Dragasac Limited

Sorrento Therapeutics

Starr Insurance Companies

Alumni Ventures

Heritage Group

Human Longevity

Section 32 Celgene

United Therapeutics

Bill Maris

Tony Robbins

We're excited for the future here at Celularity and are off to an invigorating 2024! Net sales expectations and updates can be found in the full release, linked below.

Exciting announcement! The opportunity to manufacture placental-derived biomaterials for distribution by BioCellgraft will bring our exceptional, proven technology to the management of oral healthcare concerns and fill the treatment gap for patients who suffer from soft tissue and hard tissue conditions.

Excited about the future at Celularity!
https://lnkd.in/gmJmRJCP

We're pleased to have had our Chairman, CEO and Founder, Dr. Bob Hariri, featured by Cell & Gene .  Discussion topics included lessons learned in allogeneic cell therapy, advice for allogeneic cell therapy start-ups, the strategy behind the Celularity facility, and more. 
#celltherapy #cellandgenetherapy 
https://lnkd.in/dj2Sr_3c

We’re pleased to announce our exclusive U.S. commercialization agreement with Verséa Health (Verséa Ophthalmics), which will allow us to support eye care professionals as they treat ocular surface diseases and perform certain ocular surgeries. Discover more about the partnership: https://bit.ly/3YcZdOM

Next Wednesday, July 26, our team will present data on Celularity’s proprietary #biomaterials at the International Conference on Biomaterials Science and Tissue Engineering (ICBSTE) in Osaka, Japan.

Presented by Anna Gosiewska, PhD, the data will include three benchtop and clinical case studies for three Celularity human placental-derived advanced biomaterial products. Find out more about the data here: https://bit.ly/3JY4LXS

Check out this interview with our Chairman, CEO and Founder, Dr. Bob Hariri, in the latest issue of Pulse 2.0
https://lnkd.in/ejr2bu6X

Next month, Celularity will present at the 7th International Conference on Orthopedics in Rome. The oral session will share data from a new technology in development for orthopedic applications.
 
Read the full announcement to learn more about the study: https://bit.ly/3NpgMGA

Exciting update: data featured in the journal Cytotherapy demonstrate that CRISPR-mediated tissue factor (TF) gene knock out (TFKO) in allogeneic stromal cells (ASCs) leads to significantly lower TF expression, activity, and thrombotic effects. This #preclinical #data from an edited version of one of our cell therapy candidates signals a feasible pathway to potentially improve the safety of ASC-based #celltherapy.
 
Full details here: https://bit.ly/3qjvHua

Today, we are excited to announce that we have received a $45 million purchase order for Celularity private label Halal-Certified #biomaterial products from Jamjoom Medicine Store.
 
This marks the first purchase order received under our recently announced expansion into the Middle East market, as part of our global market strategy. Read the full announcement: https://bit.ly/426nqXw

	Dec '19	Dec '20	Dec '21	Dec '22
revenue	21.15M -	14.28M 32.48%	21.34M 49.43%	17.98M 15.75%
cost of revenue	6.32M -	4.93M 22.01%	9.65M 95.72%	19.66M 103.72%
gross profit	14.82M -	9.35M 36.95%	11.68M 24.99%	-1.69M 114.47%
selling and marketing expenses	1.16M -	764K 34.02%	252K 67.02%	163K 35.32%
general and administrative expenses	564.34K -	30.57M 5,317.31%	71.09M 132.53%	65.86M 7.36%
selling general and administrative expenses	1.68M -	31.34M 1,761.32%	71.34M 127.66%	66.02M 7.46%
research and development expenses	46.05M -	52.71M 14.45%	88.35M 67.63%	78.36M 11.31%
other expenses		3.39M -	50.75M 1,395.37%	2.19M 95.68%
cost and expenses	1.68M -	92.37M 5,386.59%	169.35M 83.34%	166.24M 1.83%
operating expenses	1.68M -	87.44M 5,093.64%	159.69M 82.64%	146.58M 8.21%
interest expense	-3.75M -	2.35M 162.85%	3.17M 34.71%	-164.78M 5,296.34%
ebitda	-1.68M -	-65.45M 3,787.70%	-96.93M 48.09%	-141.13M 45.61%
operating income	-1.68M -	-78.09M 4,538.50%	-148.01M 89.54%	-25.60M 82.70%
depreciation and amortization	6.19M -	12.64M 104.33%	51.09M 304.15%	-115.53M 326.16%
total other income expenses net	8.23M -	-134.84M 1,738.31%	47.91M 135.53%	39.80M 16.92%
income before tax	6.55M -	-212.93M 3,352.38%	-100.10M 52.99%	14.21M 114.19%
income tax expense	668.23K -	-4.70M 803.35%	20K 100.43%	13K 35%
net income	5.88M -	-208.23M 3,642.12%	-100.12M 51.92%	14.19M 114.18%
weighted average shs out	3.46M -	1.84M 46.80%	6.71M 264.09%	13.99M 108.64%
weighted average shs out dil	3.46M -	1.84M 46.80%	6.71M 264.09%	14.98M 123.44%
eps	1.70 -	-113.06 6,750.59%	-14.93 86.79%	1.01 106.76%
epsdiluted	1.70 -	-113.06 6,750.59%	-14.93 86.79%	0.95 106.36%

NASDAQ:CELU

Celularity Inc.

Last Close

2.99

26/07 20:00

Market Cap

61.43M

Beta: 0.21

Volume Today

7.66K

Avg: 494.12K

PE Ratio

−0.49

PFCF: −1.49

Preview